Table 2a. Stent Thrombosis and Major Adverse Cardiovascular and Cerebrovascular Events (MACCE).

Subjects were randomized to 18 months of either continued thienopyridine or placebo plus aspirin 12 months after receiving a drug-eluting stent. Data are presented according to intention-to-treat. The primary analysis period was 12-30 months after enrollment, and the study co-primary effectiveness end points were stent thrombosis and MACCE. Hazard ratios are presented as continued thienopyridine vs. placebo.

Outcome	Continued Thienopyridine N=5020	Placebo N=4941	Stratified Hazard Ratio (95% CI)	Stratified Log-rank P Value
Stent thrombosis	19 (0.4%)	65 (1.4%)	0.29 (0.17, 0.48)	<0.001
ARC definite	15 (0.3%)	58 (1.2%)	0.26 (0.14, 0.45)	<0.001
ARC probable	5 (0.1%)	7 (0.1%)	0.71 (0.22, 2.23)	0.55
MACCE (death, MI, or stroke)	211 (4.3%)	285 (5.9%)	0.71(0.59, 0.85)	<0.001
Death	98 (2.0%)	74 (1.5%)	1.36 (1.00, 1.85)	0.052
Cardiac	45 (0.9%)	47 (1.0%)	1.00 (0.66, 1.52)	0.98
Vascular	5 (0.1%)	5 (0.1%)	0.98 (0.28, 3.39)	0.98
Non-cardiovascular	48 (1.0%)	22 (0.5%)	2.23 (1.32, 3.78)	0.002
MI	99 (2.1%)	198 (4.1%)	0.47 (0.37, 0.61)	<0.001
Stroke	37 (0.8%)	43 (0.9%)	0.80 (0.51, 1.25)	0.32
Ischemic	24 (0.5%)	34 (0.7%)	0.68 (0.40, 1.17)	0.16
Hemorrhagic	13 (0.3%)	9 (0.2%)	1.20 (0.50, 2.91)	0.68
Type uncertain	0 (0.0%)	1 (0.0%)	0 (--, --)	0.32

Abbreviations: ARC, Academic Research Consortium; ASA, aspirin; MACCE, major adverse cardiovascular and cerebrovascular events; MI, myocardial infarction; ST, stent thrombosis.